SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and...

TARRYTOWN, N.Y., December 19, 2024 – Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer...

December 17, 2024 -- New NIH-funded data show lower use of most substances continues following the COVID-19 pandemic. If you or someone you know is struggling or in crisis, help is available. Call or text 988 or chat at 988lifeline.org. To learn...

SALT LAKE CITY, Dec. 17, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and...

RAHWAY, N.J.--(BUSINESS WIRE) December 16, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and...

Brussels, Belgium – 16 December 2024 -- UCB today announced the ORCHESTRA proof-of-concept study of minzasolmin - an investigational, oral small molecule, alpha-synuclein misfolding inhibitor - developed in partnership with Novartis for early...

December 13, 2024 -- On December 5, 2024, Lilly requested that the U.S. Food and Drug Administration revoke the Emergency Use Authorization for bebtelovimab since all lots of bebtelovimab manufactured and labeled for use under EUA 111 have expired...

December 13, 2024 -- On November 22, 2024, GSK requested that the U.S. Food and Drug Administration revoke the Emergency Use Authorization for sotrovimab since all lots of sotrovimab manufactured and labeled for use under EUA 100 have expired. At...

December 13, 2024 -- On November 25, 2024, Regeneron requested that the U.S. Food and Drug Administration revoke the Emergency Use Authorization for REGEN-COV (Casirivimab and Imdevimab) since all lots of REGEN-COV manufactured and labeled for use...

December 13, 2024 -- On November 21, 2024, AstraZeneca requested that the U.S. Food and Drug Administration revoke the Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab) since all lots of Evusheld distributed under...

Paris, December 13, 2024. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). This is based on...

SAN FRANCISCO--(BUSINESS WIRE) December 12, 2024 -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and European Medicines...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Dec. 12, 2024-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive data from its...

December 12, 2024 -- Pilatus Biosciences Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for the treatment of liver and intrahepatic bile duct...

INDIANAPOLIS, Dec. 11, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader (SERD), in patients with estrogen...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 11, 2024-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and...

December 10, 2024 -- The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data...

LOS ANGELES, Dec. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that its Phase 2b/3...

GAITHERSBURG, Md., Dec. 10, 2024. Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, today announced that the first participants have been dosed in its COVID-19-Influenza Combination (CIC) and stand-alone...

Copenhagen, Denmark, December 10, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that...

LEXINGTON, Mass. and AMSTERDAM, Dec. 10, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company reached...

DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that...

TARRYTOWN, N.Y., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data for odronextamab were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in...

9 December 2024 -- Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small...

RAHWAY, N.J.--(BUSINESS WIRE) December 8, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin...